• About us
• Contact

Advertisement

Product › Details

adoptive cellular therapy (ACT)

	Next higher product group	cell therapy
	Status	2015-08-26 development existent

Record changed: 2024-06-07

Advertisement

More documents for cell therapy

• [1] Roche. (11/26/24). "Press Release: Roche Enters into a Definitive Agreement to Acquire Poseida Therapeutics, Including Cell Therapy Candidates and Related Platform technologies". Basel....
• [2] Medigene AG. (11/26/24). "Press Release: Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment". Basel....
• [3] CRISPR Therapeutics AG. (11/5/24). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results". Zug & Boston, MA....
• [4] Invios GmbH. (10/15/24). "Press Release: Invios Raises €8.2 Million in a Series A to Finance Pipeline Progress in Immuno-oncology". Vienna....
• [5] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen....
• [6] Miltenyi Biotec B.V. & Co. KG. (9/10/24). "Press Release: Miltenyi Biotec Manufactures Lentiviral Vector for Adaptimmune’s FDA-approved TCR T-cell therapy Tecelra (afamitresgeme autoleucel)". Bergisch Gladbach....
• [7] Medigene AG. (9/5/24). "Press Release: Medigene Announces U.S. FDA Clearance of IND Application for MDG1015 for Multiple Solid Tumor Indications". Planegg....
• [8] CRISPR Therapeutics AG. (8/5/24). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results". Zug & Boston, MA....
• [9] Adaptimmune Therapeutics plc. (8/1/24). "Press Release: Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor". Philadeliphia, PA & Oxford....
• [10] Immatics N.V.. (7/31/24). "Press Release: Immatics Appoints Alise Reicin to Board of Directors". Houston, TX & Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.